Clinical Trials – Advancing Autoimmune Research
YTB323 Study – A Milestone in Autoimmune Therapy
We are proud to have successfully treated the first SLE patient in Australia with YTB323 (Novartis), a cutting-edge CAR-T cell therapy. Although this study is now closed to recruitment, it represents a major advancement in the treatment of autoimmune conditions.
- Monash Nephrology are currently recruiting Lupus Nephritis patients for the Phase II YTB study
Coming in March 2026: Allogeneic CAR-T Study
Launching by late 2026, a second allogeneic CAR-T study will focus on:
- Systemic Lupus Erythematosus (SLE)
- Systemic Sclerosis (Scleroderma)
- Rheumatoid Arthritis
- Idiopathic Inflammatory Myositis
This study is conducted in close partnership with Monash Haematology, reinforcing our commitment to collaborative, multidisciplinary care and research excellence.
For referrals or more information, contact:
Professor Eric Morand – RheumatologyClinicalTrials@monashhealth.org
Phase III Sjögren’s Disease Study – Now closed to recruitment
This website will be regularly updated with any future Sjogren’s studies
Coming in March/April 2026-a Phase III study for
- DLE/SCLE (with or without SLE)-(CLASI>8)
- ACLE with SLE-(CLASI>8)
This study is for 6 months, an oral agent with option of open-label extension. Details to come.
Also coming in March 2026 – exciting new T Cell Engager study
This open label, Phase I study is for severe refractory Rheumatoid Arthritis and SLE. Details to come.
- Also in @May/June 2026-exciting T Cell Engager study
This open label, Phase I study is for severe refractory Rheumatoid Arthritis and SLE
-details to come.
Coming in 2027-T Cell Engager study for Diffuse Scleroderma
Current Rheumatology clinical trials
Please open PDF file using the link below, which outlines all current clinical trials – updated quarterly with new trials.
Current Rheumatology clinical trials
PDF document